Cart
×
Edgewise Therapeutics Announces Positive 2-Month Interim Results From The ARCH Open-Label Study Of EDG-5506 In Adults With Becker Muscular Dystrophy (BMD)
Significant decreases in key biomarkers of muscle damage.
Complex Medical Equipment Justification, Appeals and Resources
Insurance companies continue to deny complex medical equipment for patients whom it is medically necessary. The rules keep changing. It can be difficult to keep up with the latest equipment […]
Sarepta Clinical Trials Community Bulletin
Sarepta Therapeutics is currently running multiple clinical trials in a few different countries. They are at various stages and for a range of ages. Sarepta issued an update for the […]
Code Biotherapeutics Raises $75 Million in Series A Financing
CureDuchenne Ventures is pleased to share that one of our research investments, Code Bio, has announced that have secured $75 million in additional investments to advance their gene therapy programs […]
Nationwide Researchers Announce Restoration of Full-Length Dystrophin in Humans
We’re thrilled to announce that researchers at Nationwide Children’s Hospital have documented the first-ever creation of full-length dystrophin in a human as a response to gene therapy. CureDuchenne has contributed […]
CUREDUCHENNE ADDS VICE PRESIDENT OF RESEARCH AND PARTNER OF VENTURES
Lianna Orlando, PhD and Bradley Hodges, PhD Bring Scientific and Investment Expertise to Global Rare Disease Nonprofit’s Venture Philanthropy Team Newport Beach, Calif. – May 13, 2022 – CureDuchenne, a […]
Pfizer CIFFREO Webinar
Pfizer’s Global Clinical Lead for Rare Neurological Diseases, Beth Belluscio, MD-PhD, and Debra Miller, Founder and CEO of CureDuchenne, sat down to educate the Duchenne community on Pfizer’s CIFFREO Trial […]
Entrada Presents New Data
Entrada Therapeutics announced encouraging new data on their exon 44 skipping program following their presentation at TIDES USA 2022. CureDuchenne provided funding to Entrada last year as part of their Series […]